|Day Low/High||42.61 / 43.97|
|52 Wk Low/High||31.47 / 54.13|
The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.
Abbott Labs shares have been all over the place in the last year as the company makes deals. Investors are wondering if they should hold on.
The cardiac device maker has filed a lawsuit against the Muddy Waters, claiming the short-seller intentionally disseminated false and misleading information.
Potential targets of the medical device and diagnostics giant might request stricter parameters when structuring a deal, company followers say.
Alere claims that Abbott is slow-rolling the antitrust process on the companies' merger in an effort to kill the deal.
In a newly unsealed lawsuit, Alere (ALR) claims that Abbott (ABT) blocked the companies' $7.9 billion merger once it experienced 'buyer's remorse.'
The provider of point-of-care testing has filed a suit in Delaware Chancery Court against Abbott in an effort to complete their pending deal. Meanwhile, St. Jude, gets a griping short-seller.
Latest testing application on innovative Alere i molecular diagnostic platform detects RSV infections in 13 minutes or less
New Alere Reader Provides Consistency and Connectivity of Alere BinaxNOW® Legionella and S. pneumoniae Tests
New Manesar factory to produce critical diagnostics for detection of Malaria, Dengue, HIV and other infectious diseases
Alere (ALR) stock is rebounding today as concerns surrounding the Wall Street Journal's report fade of a subpoena from the Justice Department.
TheStreet highlights 3 stocks pushing the health care sector higher today.
Trade-Ideas LLC identified Alere (ALR) as a "dead cat bounce" (down big yesterday but up big today) candidate
Shares of Alere (ALR) closed lower today after it was revealed that the Justice Department is seeking a criminal probe into the company's billing practices, CNBC's DeAngelis said.
Trade-Ideas LLC identified Alere (ALR) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
The medical device company has two pending acquisitions worth just under $40 billion combined.
TheStreet highlights 3 stocks pushing the drugs industry higher today.
Alere (ALR) stock is rising on Friday morning after the company said it expects to restate financial results and was upgraded to ‘buy’ at Canaccord Genuity.
Trade-Ideas LLC identified Alere (ALR) as a pre-market mover with heavy volume candidate
Broadened Access to a New 4th-generation Test in Resource-limited Countries Increases Opportunities to Meet Ambitious New Goals for Screening and Linkage to Care
Developing countries can now add point-of-care molecular Early Infant Diagnosis to national health algorithms, facilitating immediate linkage to care for HIV-positive newborns
Lundin Law PC announces a class action lawsuit has been filed against Alere Inc.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Alere Inc.